产地国家：日本 处方药：是 所属类别： 50毫克/胶囊 100胶囊/盒 包装规格： 50毫克/胶囊 100胶囊/盒 计价单位：盒 生产厂家英文名：Nippon Kayaku Co 原产地英文商品名：Starasid Cap(スタラシドカプセル)50mg/Cap 100Cap/box 原产地英文药品名：Cytarabine Ocfosphate Hydrate 中文参考商品译名：Starasid硬胶囊(スタラシドカプセル)50毫克/胶囊 100胶囊/盒 中文参考药品译名：阿糖胞苷十八烷基磷酸盐

简介：

部份阿糖胞苷磷酸盐水合物中文资料(仅供参考)类别名称抗肿瘤药欧文商標名Starasid CapShitarabinokufosufato(抗代谢物)Sutarashido(日本化药)为抗癌及阿糖胞苷，产生的治疗药，是因为身体的同时开始启动。 DNA的功能，抑制DNA聚合酶是防止嘧啶合成的抗代谢物之一。 适应症：急性髓系白血病，骨髓增生异常综合征 副作用：骨髓抑制显着。除了恶心，呕吐，发烧，厌食，乏力，肝损害可能发生。还有一个间质性肺炎的危险。最初症状，如咳嗽和呼吸困难。 使用说明：减少骨髓造血功能和感染，症状可能会恶化，由于药物的行动。有肝损伤，可能会出现强烈的副作用。 Cytarabine Ocfosfate是一种口服有效的阿糖胞苷硬脂酸盐衍生物，由Yamasa Corporation和Nippon Kayaku共同开发。1992年该药在日本以商品名Starasid上市，用于治疗骨髓发育不良综合征(MDS)和白血病(Company communicatins，Yamasa，Mar1993&Jan 1994;Scrip，1992，1649，8)。Asta Medica Kayaku(Asta Medica/Nippon Kayaku合资)在西欧进行了该药的Ⅱ期临床试验(Company communication，Asta Medica，Mar1993;Ann Rep，Asta Medica，1993/94)。NipponKayaku计划与Yamasa Shoyu合作在东欧对该药进行开发(Scrip，1995，1993，16)，在日本以外地区的开发在继续进行中(Company communication，Nippon Kayaku，Jan 1997)。 包装规格：胶囊剂50mg：40粒 100粒；100mg：40粒

英文版说明书：

Staraside CapEffects of this medicineThis medicine inhibits DNA (deoxyribonucleic acid) synthesis of cancer cells to suppress their growth.It is used to treat adult acute non-lymphatic leukemia or myelodysplastic syndrome.Before using this medicine, be sure to tell your doctor and pharmacist•If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.If you are a patient with marrow depression, infection, liver disorder.•If you are pregnant or breastfeeding.•If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)Dosing schedule (How to take this medicine)•Your dosing schedule prescribed by your doctor is <>•For adult acute non-lymphatic leukemia: In general, for adults, take 2-6 capsules (100-300mg of the active ingredient anhydride) in 1-3 divided doses a day after meal.For myelodysplastic syndrome: In general, for adults, take 2-4 capsules (100-200mg of the active ingredient anhydride) in 1-3 divided doses a day after meal, for 2 to 3 weeks every day, then discontinue the medication for 2-3 weeks and repeat this schedule. The dosage may be adjusted according to your disease or symptoms.Strictly follow the instructions.•If you miss a dose, take the missed dose as soon as possible. If it is almost time for the next dose, skip the missed dose and follow your regular dosing schedule. You should never take two doses at one time.•If you accidentally take more than your prescribed dose, consult with your doctor or pharmacist.•Do not stop taking this medicine unless your doctor instructs you to do so.Precautions while taking this medicine• Possible adverse reactions to this medicineThe most commonly reported adverse reactions include loss of appetite, nausea/vomiting, fever, malaise and rash. If any of these symptoms occur, consult with your doctor or pharmacist.The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.•anemia, fever, bleeding tendency (nasal bleeding, bleeding gums, bleeding under the skin), malaise [marrow depression include pancytopenia]•fever, dry cough, breathing difficulty [interstitial pneumonia]The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.Storage conditions and other information•Keep out of the reach of children. Store away from direct sunlight, heat and moisture.•Discard the remainder. Do not store them. Ask your pharmacist how to discard.NIPPON KAYAKUInternalPublished: 3/2008The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.